reports
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-Hi...
Beyond Cancer Abstract Featuring Phase 1 Data on Intratumoral Ultra-High Concentration Nitric Oxide (UNO) in Solid Tumor Metastases to be Presented at the AACR Annual Meeting 2026 GARDEN CITY, N.Y., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), today announced being selected to present an abstract featuring data from the Phase 1 trial of intratumoral UNO in solid tumor metastases at the American A...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferen...
Beyond Air to Participate in Two Upcoming Healthcare Investor Conferences GARDEN CITY, N.Y., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that Steve Lisi, Chairman & Chief Executive Officer of Beyond Air, will participate in the 13th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference being held February 9th to 11th in Snowbird, UT and the Noble Cap...
Team, Inc. Announces Planned Leadership Transition and Names Gary Hill...
Team, Inc. Announces Planned Leadership Transition and Names Gary Hill as Chief Executive Officer SUGAR LAND, Texas, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a leading provider of specialty industrial services offering a full suite of mechanical, heat-treating, and inspection services around the world, today announced that Keith Tucker will retire from Team after over 20 years of service. In conjunction with this planned leadership transition, TEAM’s Board of Directors has appointed Gary Hill as the Company’s Chief Executive Officer effective Fe...
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Confe...
Beyond Air Schedules Third Fiscal Quarter 2026 Financial Results Conference Call and Webcast GARDEN CITY, N.Y., Jan. 26, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that it will report financial results for its third fiscal quarter ended December 31, 2025 on Friday, February 13, 2026. The Company's management team is scheduled to host a conference call and webcast at 8:00 am East...
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Mark...
Beyond Air Announces $5.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules GARDEN CITY, N.Y., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide to improve the lives of patients, today announced that it entered into a securities purchase agreement with an institutional investor to issue and sell, in a private placement priced at-the-market under Nasdaq rules, 3,930,818 shares of common stock (or pre-funded warrants...
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized...
IMDX Supports AST and ASHI STAR Working Group’s Call for Decentralized Transplant Monitoring American Journal of Transplantation position paper also highlights value of absolute quantification of dd-cfDNA as a diagnostic marker, a key feature of iMDx’s flagship GraftAssureTM family of assays NASHVILLE, Tenn., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), (iMDx), today congratulated the STAR working group on its position paper in the American Journal of Transplantation in recognizing the need for decentralized organ health testing in the global tran...
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNO...
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership Unmatched scientific firepower: Two Nobel Laureates join Founder Prof. Haitham Amal, leading global autism researcher Critical unmet need: 1 in 31 U.S. children now affected, zero FDA-approved disease-modifying therapies exist FDA Orphan Drug designations secured for autism-related Phelan-McDermid Syndrome (PMS) and Glioblastoma Platform targets the core biology of autism, not just symptomatic relief Beyond Air (NASDAQ: XAIR), majorit...
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation
iMDx Announces “JPM Week” and “BTIG Snowbird” Conference Participation NASHVILLE, Tenn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today announced members of its management team will participate in the following investor conferences this winter, which will include hosting meetings around the annual J.P. Morgan Healthcare Conference. LifeSci Advisors 15th Annual Corporate Access Event Date: Monday, January 12thLocation: The Beacon Grand, San Francisco, Calif.Format: One-on-one meetings with management Additional “JPM Week” Investor Mee...
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs ...
iMDx to Welcome Industry Veteran as Vice President of Medical Affairs to Prepare for Commercial Transplant Assay Launch Dr. Nick Ioannou brings decades of academia, industry, and clinical experience in organ transplant, nephrology, cardiology, genetics, and oncology NASHVILLE, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX), or iMDx, today announced that it has appointed Dr. Nick Ioannou, M.D., MHA, to the position of Vice President, Medical Affairs. Dr. Ioannou is a physician-scientist with more than three decades of highly relevant experienc...
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical ...
iMDx Prepares for U.S. Commercial Launch of GraftAssureDx as Clinical Trial Nears Completion GraftAssure™ technology adoption further broadens with 20 global transplant centers engaged by year-end 2025, including first Canadian siteGraftAssureDx™ FDA IVD approval application 95% complete at year-end; expect full submission in coming weeksAccelerating planned UK CE mark and EU IVDR submission to first half 2026, following successful TÜV SÜD ISO 13485 stage 1 & 2 audit completions in Q4 2025Strong engagement from clinical community on GraftAssureCore™ kidney registry with 17 U.S. transplant c...
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer
Beyond Air® Appoints Dan Moorhead as Chief Financial Officer GARDEN CITY, N.Y., Dec. 30, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the appointment of Dan Moorhead as Chief Financial Officer, effective January 5, 2026. Duke Dewrell, the Company's Controller, who had assumed CFO responsibilities at the Company on an interim basis in November 2025, will resume his prior role as of...
Beyond Air® Signs New International LungFit PH® Distribution Agreement...
Beyond Air® Signs New International LungFit PH® Distribution Agreements, Most Notably in Germany and Brazil Distribution network coverage expanded to a total of 39 countries GARDEN CITY, N.Y., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced the recent signing of several key international distribution agreements for LungFit® PH, expanding its network to include Germany, Bra...
- Jonathan Moreland
ZEUS OLYMPIC STEEL INC.
XOMA XOMA
NWBI NORTHWEST BANCSHARES INC.
NRIM NORTHRIM BANCORP INC.
MERC MERCER INTERNATIONAL INC.
MCY MERCURY GENERAL CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CRM SALESFORCE.COM INC.
CE CELANESE CORPORATION
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
AMH AMERICAN HOMES 4 RENT CLASS A
MGM MGM RESORTS INTERNATIONAL
OXM OXFORD INDUSTRIES INC.
RSG REPUBLIC SERVICES INC.
MHH MASTECH DIGITAL
WMG WARNER MUSIC GROUP CORP.
NHF NEXPOINT CREDIT STRATEGIES FUN
PMTS CPI CARD GROUP
NWPP NEW PEOPLES BANKSHARES INC.
MIDD THE MIDDLEBY CORPORATION
AVTR AVANTOR
SELF INC.
ALTG SELF STORAGE GROUP
IMVT INC.
ORIC ALTA EQUIPMENT GROUP INC.
NOG IMMUNOVANT INC
MRVI ORIC PHARMACEUTICALS
DMAC NORTHERN OIL AND GAS
AMR MARAVAI LIFESCIENCES HOLDINGS
NRDY DIAMEDICA THERAPEUTICS INC.
ABSI ALPHA METALLURGICAL RESOURCES INC
IMMX NERDY INC.
LUCY ABSCI CORP
LIN IMMIX BIOPHARMA INC
MNR INNOVATIVE EYEWEAR INC
XELB LINDE PUBLIC LIMITED COMPANY
FEAM MACH NATURAL RESOURCES LP
SEVN XCEL BRANDS INC.
5E ADVANCED MATERIALS INC.
SEVEN HILLS REALTY TRUST
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
NRIM NORTHRIM BANCORP INC.
FFIN FIRST FINANCIAL BANKSHARES INC
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
MLP MAUI LAND & PINEAPPLE CO. INC.
ALTG ALTA EQUIPMENT GROUP INC.
AMR ALPHA METALLURGICAL RESOURCES INC
NEXT NEXT CAPITAL
NRDY NERDY INC.
IMMX IMMIX BIOPHARMA INC
QDEL QUIDEL CORP
SMRT SMARTRENT INC
MNR MACH NATURAL RESOURCES LP
GAM GENERAL DE ALQUILER DE MAQUINARIA
TENX TENAX THERAPEUTICS INC.
AFCG AFC GAMMA
INC.
Beyond Air® Announces Transition of Chief Financial Officer
Beyond Air® Announces Transition of Chief Financial Officer Launched search for permanent successor GARDEN CITY, N.Y., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that Doug Larson has resigned as Chief Financial Officer to pursue another opportunity. Mr. Larson will continue to serve as CFO through December 5, 2025, at which time the CFO responsibilities at the Company...
Team, Inc. Reports Third Quarter 2025 Results
Team, Inc. Reports Third Quarter 2025 Results SUGAR LAND, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global, leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today reported its financial results for the quarter ended September 30, 2025. Third Quarter 2025 Highlights: Generated revenue of $225.0 million, up $14.2 million, or 6.7% over the third quarter of 2024.Grew gross margin to $58.0 million, a $...
Team, Inc. Announces Timing Of Third Quarter Earnings Release And Conf...
Team, Inc. Announces Timing Of Third Quarter Earnings Release And Conference Call SUGAR LAND, Texas, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Team, Inc. (NYSE: TISI) (“TEAM” or the “Company”), a global leading provider of specialty industrial services offering customers access to a full suite of conventional, specialized, and proprietary mechanical, heat-treating, and inspection services, today announced that it will issue its third quarter 2025 earnings release on Wednesday, November 12, 2025 after the close of trading on the New York Stock Exchange. TEAM will host a conference call to discuss ...
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and P...
Beyond Air® Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update Increased revenue by 128% year over year (YoY) to $1.8 million Appointed Beyond Air Board member Bob Goodman as Interim Chief Commercial Officer Raised $12.0 million in debt financing; proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025 Achieves certificate for Medical Device Single Audit Program (MDSAP) Updated fiscal year 2026 revenue guidance to $8 – $10 million Conference call at 4:30 p.m. ET today, November 10th GARDEN CI...
IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launc...
IMDX Reports Q3 2025 Results and Progress Toward 2026 Commercial Launch On track to submit GraftAssureDx™ for FDA review by year-endOn track for commitment to have 20 transplant centers globally engaged with GraftAssure technology by end of 2025GraftAssure assay’s head-to-head data continue to be favorablePreparing to rapidly expand beyond kidney into heart transplant testing NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., or iMDx, (Nasdaq: IMDX), today published the following letter to shareholders in conjunction with its third quarter results: ...
Beyond Air® Secures Up to $32 Million to Accelerate Growth
Beyond Air® Secures Up to $32 Million to Accelerate Growth Enters agreements for a $12 million promissory note and a $20 million equity line of credit with Streeterville Capital Proforma cash, cash equivalents, restricted cash and marketable securities of $22.9 million as of September 30, 2025, including $12 million from the promissory note Extends cash runway into calendar 2027 GARDEN CITY, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the p...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.